Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Nauck, Michael (35230348700)"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Report from the 5th cardiovascular outcome trial (CVOT) summit
    (2020)
    Schnell, Oliver (7006418720)
    ;
    Standl, Eberhard (7102763320)
    ;
    Cos, Xavier (36518397900)
    ;
    Heerspink, Hiddo Jl (57210045376)
    ;
    Itzhak, Baruch (6506006834)
    ;
    Lalic, Nebojsa (13702597500)
    ;
    Nauck, Michael (35230348700)
    ;
    Ceriello, Antonio (7102926564)
    The 5th Cardiovascular Outcome Trial (CVOT) Summit was held in Munich on October 24th-25th, 2019. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and presented CVOTs. This year, focus was placed on the CVOTs CAROLINA, CREDENCE, DAPA-HF, REWIND, and PIONEER-6. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussions evolved from CVOTs to additional therapy options for heart failure (ARNI), knowledge gained for the treatment and prevention of heart failure and diabetic kidney disease in populations with and without diabetes, particularly using SGLT-2 inhibitors and GLP-1 receptor agonists. Furthermore, the ever increasing impact of CVOTs and substances tested for primary prevention and primary care was discussed. The 6th Cardiovascular Outcome Trial Summit will be held in Munich on October 29th-30th, 2020 (https://www.cvot.org). © 2020 The Author(s).
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
    (2022)
    Schnell, Oliver (7006418720)
    ;
    Battelino, Tadej (8726399700)
    ;
    Bergenstal, Richard (35394824100)
    ;
    Blüher, Matthias (6602576090)
    ;
    Böhm, Michael (35392235500)
    ;
    Brosius, Frank (7006362998)
    ;
    Carr, Richard D. (7202146459)
    ;
    Ceriello, Antonio (7102926564)
    ;
    Forst, Thomas (7006334793)
    ;
    Giorgino, Francesco (7006329053)
    ;
    Guerci, Bruno (7005678840)
    ;
    Heerspink, Hiddo J. L. (57210045376)
    ;
    Itzhak, Baruch (6506006834)
    ;
    Ji, Linong (57225730408)
    ;
    Kosiborod, Mikhail (9040082100)
    ;
    Lalić, Nebojša (13702597500)
    ;
    Lehrke, Michael (57203333460)
    ;
    Marx, Nikolaus (57203048581)
    ;
    Nauck, Michael (35230348700)
    ;
    Rodbard, Helena W. (6507427022)
    ;
    Rosano, Giuseppe M. C. (7007131876)
    ;
    Rossing, Peter (7005170096)
    ;
    Rydén, Lars (56443609500)
    ;
    Santilli, Francesca (6602626251)
    ;
    Schumm-Draeger, Petra-Maria (7005030702)
    ;
    Vandvik, Per Olav (6602321455)
    ;
    Vilsbøll, Tina (6701375328)
    ;
    Wanner, Christoph (57212349814)
    ;
    Wysham, Carol (7801373715)
    ;
    Standl, Eberhard (7102763320)
    The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year’s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed. Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 (http://www.cvot.org). © 2022, The Author(s).

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback